钙离子增敏剂治疗慢性心力衰竭失代偿患者的临床疗效和安全性观察

doi:10.3969/j.issn.1006-6233.2018.10.019

Abstract
Figure/Table
References
Related Citation (7)

Download: PDF (3969 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the efficacy and safety of calcium sensitizer(levosimendan)in treatment of chronic decompensated congestive heart failure. Methods: 97 patients with decompensated NYHA grade III to IV heart function were enrolled in our hospital from October 2016 to October 2017. All the patients were randomly divided into comentional treatment group (45 cases) and levosimendan group (52 cases). The comentional treatment group was treated with standardized drugs (including diuretics, aldosterone receptor antagonists, digitalis, ACEI/ARB, beta blockers, etc.). Levosimendan group was treated with levosimendan pump on the basis of comentional treatment. Left ventricular ejection fraction (LVEF) was measured 24 hours after admission and 7 days after treatment. NT-proBNP and biochemical indexes (creatinine, ALT, AST) were measured in the morning plasma and glomerular filtration rate (eGFR) was calculated. The NYHA cardiac function grades of the two groups before and after treatment were evaluated. Results: On the 7th day of treatment, the LVEF, NT-proBNP, urine volume and NYHA cardiac function of the comentional treatment group and the levosimendan group were improved after treatment, and the difference was statistically significant (P<0.05). However, the levosimendan group had higher LVEF, lower NT-proBNP, and higher urine volume than the conventional treatment group,the cardiac function classification of New York improved more significantly (P<0.05).Before and after treatment,Two groups of patients liver function and renal function,eGFR there was no significant difference (P>0.05). Conclusion: Early application of levosimendan in the treatment of chronic heart failure decompensated patients can significantly improve heart failure index, such as LVEF, NT-proBNP, urine output, NYHA heart function classification. It dose not damage liver and kidney function, and have good clinical effect.

Key words： Calcium sensitizer Chronic decompensated congestive heart failure LVEF eGFR NT-proBNP

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.10.019 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I10/1659

[1] 中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98~122.
[2] 中国药师协会,国家卫生计生委合理用药专家委员会.心力衰竭合理用药指南[J].中国医学前沿杂志(电子版),2016,8(09):19~66.
[3] Packer M,Colucci W,Fisher L,et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure[J].JACC: Heart Failure,2013,1(2): 103~111.
[4] Follath F, Cleland J G,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial[J].Lancet,2002.360(9328):196~202.
[5] Mebazaa A,Nieminen M S,Filippatos G S,et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β-blockers in SURVIVE[J].European Journal of Heart Failure, 2009,11(3): 304~311.
[6] Ponikowski P, Voors A A,Anker S D ,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. European Journal of Heart Failure,2016,18(8): 891~975.
[7] Klein BA ,Reiz B,Robertson I M,et al.Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C in Vitro and in Situ[J].Biochemistry,2018, 57 (15 ):2256~2265.
[8] Mebazaa A, Nieminen MS, Packer M,et al.Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial[J].JAMA,2007,297(17):1883~1891.
[9] Fedele F,Bruno N,Brasolin B,et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms[J].European Journal of Heart Failure ,2014,16(3): 281~288.
[10] Hou Z Q,Sun Z X,Su C Y,et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction[J]. Cardiovascular Therapeutics, 2013,31(2): 108~114.
[11] Jia Z,Guo M,Zhang Y Q, et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction[J].Cardiology,2014,128(2):195~201.
[12] Ortis B, Villani A,Oldani Metal. Intermittent levosimendan infusions in advanced heart failure: a real world experience[J]. Journal of International Medical Research ,2017,45(1): 361~371.
[13] Altenberger J ,Parissis J T,Costard-Jaeckle A,et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial[J].European Journal of Heart Failure, 2014,16(8):898~906.